Ian T Meredith1, Jean-François Tanguay1, Dean J Kereiakes1, Donald E Cutlip1, Robert W Yeh1, Kirk N Garratt1, David P Lee1, P Gabriel Steg1, W Douglas Weaver1, David R Holmes1, Ralph G Brindis1, Jaroslaw Trebacz1, Joseph M Massaro1, Wen-Hua Hsieh1, Laura Mauri2. 1. From Monash Heart and Monash University, Melbourne, Australia (I.T.M., W.-H.H.); Montreal Heart Institute, Université de Montréal, Québec, Canada (J.-F.T.); The Christ Hospital Heart and Vascular Center and The Lindner Center for Research and Education, Cincinnati, OH (D.J.K.); Beth Israel Deaconess Medical Center, Boston, MA (D.E.C.); Harvard Clinical Research Institute, Boston, MA (D.E.C., R.W.Y., J.M.M., L.M.); Harvard Medical School, Boston, MA (D.E.C., R.W.Y., L.M.); The Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y.); Lenox Hill Hospital, New York, NY (K.N.G.); Stanford University, Stanford, CA (D.P.L.); Université Paris-Diderot, INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris - all in Paris, National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, United Kingdom (P.G.S.); Henry Ford Medical Group, Detroit, MI (W.D.W.); Mayo Clinic, Rochester, MN (D.R.H.); Institute for Health Policy Studies, University of California, San Francisco (R.G.B.); Jan Pawel II Hospital Krakow, Poland (J.T.); Boston University School of Public Health, Boston, MA (J.M.M.); and Brigham and Women's Hospital, Boston, MA (L.M.). 2. From Monash Heart and Monash University, Melbourne, Australia (I.T.M., W.-H.H.); Montreal Heart Institute, Université de Montréal, Québec, Canada (J.-F.T.); The Christ Hospital Heart and Vascular Center and The Lindner Center for Research and Education, Cincinnati, OH (D.J.K.); Beth Israel Deaconess Medical Center, Boston, MA (D.E.C.); Harvard Clinical Research Institute, Boston, MA (D.E.C., R.W.Y., J.M.M., L.M.); Harvard Medical School, Boston, MA (D.E.C., R.W.Y., L.M.); The Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y.); Lenox Hill Hospital, New York, NY (K.N.G.); Stanford University, Stanford, CA (D.P.L.); Université Paris-Diderot, INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris - all in Paris, National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, United Kingdom (P.G.S.); Henry Ford Medical Group, Detroit, MI (W.D.W.); Mayo Clinic, Rochester, MN (D.R.H.); Institute for Health Policy Studies, University of California, San Francisco (R.G.B.); Jan Pawel II Hospital Krakow, Poland (J.T.); Boston University School of Public Health, Boston, MA (J.M.M.); and Brigham and Women's Hospital, Boston, MA (L.M.). lmauri1@partners.org.
Abstract
BACKGROUND:Patients with diabetes mellitus (DM) are at high risk for recurrent ischemic events after coronary stenting. We assessed the effects of continued thienopyridine among patients with DM participating in the Dual Antiplatelet Therapy (DAPT) Study as a prespecified analysis. METHODS AND RESULTS: After coronary stent placement and 12 months treatment with open-label thienopyridine plus aspirin, 11 648 patients free of ischemic or bleeding events and who were medication compliant were randomly assigned to continued thienopyridine or placebo, in addition to aspirin, for 18 more months. After randomization, patients with DM (n=3391), in comparison with patients without DM (n=8257), had increased composite outcome of death, myocardial infarction (MI), or stroke (6.8% versus 4.3%, P<0.001), increased death (2.5% versus 1.4%, P<0.001), and MI (4.2% versus 2.6%, P<0.001). Among patients with DM, in a comparison of continued thienopyridine versus placebo, rates of stent thrombosis were 0.5% versus 1.1%, P=0.06, and rates of MI were 3.5% versus 4.8%, P=0.058; and among patients without DM the rates were 0.4% versus 1.4%, P<0.001 (stent thrombosis, P interaction=0.21) and 1.6% versus 3.6%, P<0.001 (MI, P interaction=0.02). Bleeding risk with continued thienopyridine was similar among patients with or without DM (interaction P=0.61). CONCLUSIONS: In patients with DM, continued thienopyridine beyond 1 year after coronary stenting is associated with reduced risk of MI, although this benefit is attenuated in comparison with patients without DM. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00977938.
RCT Entities:
BACKGROUND:Patients with diabetes mellitus (DM) are at high risk for recurrent ischemic events after coronary stenting. We assessed the effects of continued thienopyridine among patients with DM participating in the Dual Antiplatelet Therapy (DAPT) Study as a prespecified analysis. METHODS AND RESULTS: After coronary stent placement and 12 months treatment with open-label thienopyridine plus aspirin, 11 648 patients free of ischemic or bleeding events and who were medication compliant were randomly assigned to continued thienopyridine or placebo, in addition to aspirin, for 18 more months. After randomization, patients with DM (n=3391), in comparison with patients without DM (n=8257), had increased composite outcome of death, myocardial infarction (MI), or stroke (6.8% versus 4.3%, P<0.001), increased death (2.5% versus 1.4%, P<0.001), and MI (4.2% versus 2.6%, P<0.001). Among patients with DM, in a comparison of continued thienopyridine versus placebo, rates of stent thrombosis were 0.5% versus 1.1%, P=0.06, and rates of MI were 3.5% versus 4.8%, P=0.058; and among patients without DM the rates were 0.4% versus 1.4%, P<0.001 (stent thrombosis, P interaction=0.21) and 1.6% versus 3.6%, P<0.001 (MI, P interaction=0.02). Bleeding risk with continued thienopyridine was similar among patients with or without DM (interaction P=0.61). CONCLUSIONS: In patients with DM, continued thienopyridine beyond 1 year after coronary stenting is associated with reduced risk of MI, although this benefit is attenuated in comparison with patients without DM. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00977938.
Authors: Thomas A Mavrakanas; Yiannis S Chatzizisis; Karim Gariani; Dean J Kereiakes; Giuseppe Gargiulo; Gérard Helft; Martine Gilard; Fausto Feres; Ricardo A Costa; Marie-Claude Morice; Jean-Louis Georges; Marco Valgimigli; Deepak L Bhatt; Laura Mauri; David M Charytan Journal: Clin J Am Soc Nephrol Date: 2019-04-22 Impact factor: 8.237
Authors: Robert W Yeh; Dean J Kereiakes; P Gabriel Steg; Donald E Cutlip; Kevin J Croce; Joseph M Massaro; Laura Mauri Journal: J Am Coll Cardiol Date: 2017-10-31 Impact factor: 24.094
Authors: Ramzi A Ajjan; Noppadol Kietsiriroje; Lina Badimon; Gemma Vilahur; Diana A Gorog; Dominick J Angiolillo; David A Russell; Bianca Rocca; Robert F Storey Journal: Eur Heart J Date: 2021-06-14 Impact factor: 29.983
Authors: Giuseppe Gargiulo; Stephan Windecker; Bruno R da Costa; Fausto Feres; Myeong-Ki Hong; Martine Gilard; Hyo-Soo Kim; Antonio Colombo; Deepak L Bhatt; Byeong-Keuk Kim; Marie-Claude Morice; Kyung Woo Park; Alaide Chieffo; Tullio Palmerini; Gregg W Stone; Marco Valgimigli Journal: BMJ Date: 2016-11-03